A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation
Xiaorui Su, Yuxuan Li, Yupeng Ren, Mingbo Cao, Gaoyuan Yang, Jing Luo, Ziyi Hu, Haixia Deng, Meihai Deng, Bo Liu, Zhicheng Yao
Abstract
Drug resistance in hepatocellular carcinoma has posed significant obstacles to effective treatment. Recent evidence indicates that, in addition to traditional gene mutations, epigenetic recoding plays a crucial role in HCC drug resistance. Unlike irreversible gene mutations, epigenetic changes are reversible, offering a promising avenue for preventing and overcoming drug resistance in liver cancer. This review focuses on various epigenetic modifications relevant to drug resistance in HCC and their underlying mechanisms. Additionally, we introduce current clinical epigenetic drugs and clinical trials of these drugs as regulators of drug resistance in other solid tumors. Although there is no clinical study to prevent the occurrence of drug resistance in liver cancer, the development of liquid biopsy and other technologies has provided a bridge to achieve this goal.